

Supplementary table 2. Composite event rate by quartile of duration of fenofibrate use after multiple adjustment (crude and model 1 to 8)

Model	Variable	Outcome Composite Events (MI/Stroke/PCI/Cardiac Death)						p-value
		TOTAL (N)	Event (N)	PY (N)	Event (%)	PY (%)	HR	
Crude	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.435 (1.106,1.86)	0.0065
	Q2	1,465	67	4370.6	4.57%	15.3	0.958 (0.732,1.254)	0.7563
	Q3	1,266	44	3549.4	3.48%	12.4	0.76 (0.552,1.047)	0.0930
	Q4	1,265	23	4382.2	1.82%	5.2	0.342 (0.223,0.524)	<.0001
Adjusted Model 1	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.396 (1.076,1.81)	0.012
	Q2	1,465	67	4370.6	4.57%	15.3	0.989 (0.756,1.294)	0.9361
	Q3	1,266	44	3549.4	3.48%	12.4	0.788 (0.572,1.086)	0.1453
	Q4	1,265	23	4382.2	1.82%	5.2	0.357 (0.233,0.548)	<.0001
Adjusted Model 2	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.398 (1.078,1.814)	0.0115
	Q2	1,465	67	4370.6	4.57%	15.3	0.99 (0.757,1.296)	0.9428
	Q3	1,266	44	3549.4	3.48%	12.4	0.79 (0.574,1.089)	0.1502
	Q4	1,265	23	4382.2	1.82%	5.2	0.356 (0.232,0.546)	<.0001
Adjusted Model 3	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.464 (1.128,1.9)	0.0042
	Q2	1,465	67	4370.6	4.57%	15.3	0.998 (0.762,1.306)	0.9878
	Q3	1,266	44	3549.4	3.48%	12.4	0.809 (0.587,1.114)	0.1945
	Q4	1,265	23	4382.2	1.82%	5.2	0.351 (0.229,0.538)	<.0001
Adjusted Model 4	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.464 (1.128,1.901)	0.0042
	Q2	1,465	67	4370.6	4.57%	15.3	0.986 (0.753,1.291)	0.9164
	Q3	1,266	44	3549.4	3.48%	12.4	0.821 (0.595,1.131)	0.2269
	Q4	1,265	23	4382.2	1.82%	5.2	0.344 (0.224,0.527)	<.0001
Adjusted Model 5	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.466 (1.129,1.903)	0.0041
	Q2	1,465	67	4370.6	4.57%	15.3	0.987 (0.754,1.292)	0.923
	Q3	1,266	44	3549.4	3.48%	12.4	0.821 (0.596,1.132)	0.2291
	Q4	1,265	23	4382.2	1.82%	5.2	0.344 (0.225,0.528)	<.0001
Adjusted Model 6	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.466 (1.129,1.904)	0.0041
	Q2	1,465	67	4370.6	4.57%	15.3	0.974 (0.744,1.276)	0.85
	Q3	1,266	44	3549.4	3.48%	12.4	0.833 (0.605,1.149)	0.2661
	Q4	1,265	23	4382.2	1.82%	5.2	0.349 (0.227,0.535)	<.0001
Adjusted Model 7	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.507 (1.16,1.958)	0.0021
	Q2	1,465	67	4370.6	4.57%	15.3	1.001 (0.764,1.311)	0.9953
	Q3	1,266	44	3549.4	3.48%	12.4	0.812 (0.589,1.119)	0.2033
	Q4	1,265	23	4382.2	1.82%	5.2	0.352 (0.229,0.539)	<.0001
Adjusted Model 8	feno/omega -	5,057	258	16607.1	5.10%	15.5	1.00 (reference)	
	Q1	1,061	73	3188.4	6.88%	22.9	1.52 (1.169,1.977)	0.0018
	Q2	1,465	67	4370.6	4.57%	15.3	0.989 (0.755,1.296)	0.9364
	Q3	1,266	44	3549.4	3.48%	12.4	0.832 (0.604,1.148)	0.2631
	Q4	1,265	23	4382.2	1.82%	5.2	0.347 (0.226,0.532)	<.0001

Adjusted model 1: Age, Sex

Adjusted model 2: Age, Sex, income group

Adjusted model 3: Age, Sex, income group, MI history, Angina history, Other CAD history

Adjusted model 4: Age, Sex, income group, MI history, Angina history, Other CAD history, AF history, HF history, PCI history

Adjusted model 5: Age, Sex, income group, MI history, Angina history, Other CAD history, AF history, HF history, PCI history, CKD history

Adjusted model 6: Age, Sex, income group, MI history, Angina history, Other CAD history, AF history, HF history, PCI history, CKD history, BMI group, Smoking, LDL-C group

Adjusted model 7: Age, Sex, income group, MI history, Angina history, Other CAD history, AF history, BMI group, Smoking, LDL-C group, HTN history

Adjusted model 8: Age, Sex, income group, MI history, Angina history, Other CAD history, AF history, HF history, PCI history, CKD history, BMI group, Smoking, LDL-C group, HTN history, HDL-C group, TG group

*feno, fenofibrate; omega, omega-3 fatty acid; Q, quartile; PY, person-year; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease; AF, atrial fibrillation; HF, heart failure; CKD, chronic kidney disease; HTN, hypertension; TG, triglyceride